In a recently reported phase II study, second-line topoisomerase inhibition with topotecan (4 mg/m2 weekly) combined with the VEGF inhibitor ziv-aflibercept (6 mg/kg every 21 days) improved the 3-month progression-free survival (PFS) of patients with platinum-resistant small-cell lung cancer (SCLC), compared with patients with platinum-sensitive SCLC (27% versus 10%, P = 0.02). Combination therapy also improved the disease control rate compared with topotecan alone in patients with platinum-resistant SCLC (24% for combination versus 15% for topotecan, P = 0.05) and in platinum-sensitive patients, although not reaching statistical significance in the latter (25% versus 15%, P = 0.14). The median PFS and overall survival rates were similar across both groups of patients.
References
Allen, J. W. et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J. Clin. Oncol. 10.1200/JCO.2013.51.4109
Rights and permissions
About this article
Cite this article
Ziv-aflibercept is effective in platinum-resistant SCLC. Nat Rev Clin Oncol 11, 500 (2014). https://doi.org/10.1038/nrclinonc.2014.123
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.123